Alphina Therapeutics, a biotechnology company developing a best-in-class NAMPT inhibitor for the treatment of a range of solid tumor indications, has appointed Marc Damelin, Ph.D., as Chief Scientific Officer.   Dr. Damelin possesses extensive industry experience in oncology drug discovery and development across a variety of mechanisms of action. He has served in key scientific leadership roles at leading oncology-focused companies for more than 17 years and made contributions to the discovery...